Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + eribulin
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Durvalumab + eribulin is a combination therapy being investigated for the treatment of HER2-negative metastatic breast cancer (MBC) and recurrent ovarian cancer (ROC). Durvalumab is a humanized monoclonal antibody that targets the programmed cell death ligand-1 (PD-L1) receptor, while eribulin is a microtubule inhibitor with proven overall survival benefit in metastatic breast cancer. The combination aims to enhance immune responses by leveraging eribulin's ability to release tumor-associated antigens through cytotoxic chemotherapy and its potential to induce intratumoral vascular remodeling, which may improve the efficacy of immune checkpoint blockade with durvalumab.
- Other names
- Durvalumab and eribulin
02
Targets
MicrotubuleCD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on durvalumab + eribulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + eribulin.